Novartis punts a late-stage PI3K drug with a worrying safety profile to one of China’s upstart biotechs

Just months after a group of researchers warned against the further development of a worrying PI3K inhibitor project Novartis had been working on, the pharma giant licensed out the global rights to a newly active Chinese biotech.